Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adults.

ABSTRACT:

Objective

To examine potential disease-modifying effects of statin drugs, we conducted a 12-month randomized, placebo-controlled clinical trial of simvastatin in cognitively normal adults using change in CSF Alzheimer disease biomarkers as primary outcome measure.

Methods

Participants were 45-64 years old and statin-naive with normal cognition and normal or mildly elevated cholesterol. Forty-six participants completed the 1-year study per protocol (25 in the simvastatin and 21 in the placebo group). Simvastatin was titrated to 40 mg/d. CSF Aβ₄₂, total tau, and p-tau₁₈₁ were measured at baseline and after 12 months of treatment using the INNO-BIA AlzBio3 assay. We used analysis of covariance to assess differences in biomarker change from baseline between

SUBMITTER: Li G 

PROVIDER: S-EPMC5606918 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature